• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    MaxCyte Appoints Cynthia Collins to its Board of Directors

    10/15/24 8:05:00 AM ET
    $CERT
    $MXCT
    $PSTX
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CERT alert in real time by email

    ROCKVILLE, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Cynthia Collins to the Company's Board of Directors as a non-executive director, effective October 14, 2024. Collins will serve on the board's compensation committee. Following her appointment, MaxCyte's total Board of Directors will increase to 10 members.

    "I am pleased to welcome Cynthia to MaxCyte's Board of Directors," said Maher Masoud, President and CEO of MaxCyte. "Cynthia has extensive and impressive leadership experience in the fields of cell therapy and genetic medicine that will be invaluable to MaxCyte in the coming years. I look forward to working alongside her to enable a growing set of next-generation cell therapies as the premier cell engineering platform in our industry."

    Ms. Collins brings over 40 years of experience in the biotechnology industry and cell and gene medicines to MaxCyte, including her most recent role as Chief Executive Officer of Editas Medicine, where she was involved in dosing the first patient ever with an in-vivo gene modified therapy. Previously, Ms. Collins served as Chief Executive Officer of Human Longevity Inc., Chief Executive Officer/General Manager of General Electric Healthcare's Cell Therapy and Lab Businesses, and Chief Executive Officer of GenVec, Inc., a vaccine and gene therapy company.

    Currently, Ms. Collins serves as a member of the Board of Directors of several healthcare companies, including Alanis Therapeutics, Nutcracker Therapeutics, Poseida Therapeutics (NASDAQ:PSTX), Certara (NASDAQ:CERT), DermTech (OTC:DMTKQ), Draper Laboratory, and Panavance Therapeutics. She is also a board member of the Foundation for mRNA Medicines.

    Cynthia Collins holds a Bachelor of Science degree in Microbiology from the University of Illinois, Urbana and an MBA from The University of Chicago Booth School of Business.

    "I am honored to join MaxCyte's Board of Directors, where I believe there is exceptional work being done to propel the cell and genetic medicine industry forward," said Cynthia Collins. "I am excited to support the Company's growth and innovation as they continue to help developers bring a new class of therapies to market."

    Regulatory Disclosures

    In accordance with Rule 17, Schedule Two paragraph (g) of the AIM Rules for Companies, Cynthia Lynne Collins (66) holds, or has held, the following directorship or partnerships in the last five years:

    CurrentPast 5 years
    Alanis Therapeutics, Inc.Triumvira Immunologics, Inc.
    Nutracker Therapeutics, Inc.Biocare Medical LLC
    Panavance Therapeutics, Inc.Human Longevity, Inc.
    The Charles Stark Draper Laboratory, Inc.Editas Medicine, Inc.
    Poseida Therapeutics, Inc.ARM Foundation for Cell and Gene Medicine
    Certara, Inc. 
    DermTech Inc. 
    The Foundation for MRNA Medicines, Inc. 

    Cynthia Collins, was previously appointed as an independent director to the Board of DermTech, Inc. on May 24, 2018. On June 18, 2024, the Company filed for Chapter 11 bankruptcy. On August 21, 2024 the US Bankruptcy Court for the District of Delaware approved the sale of a substantial amount of DermTech Inc.'s assets through a court-supervised auction.

    Save as disclosed above, there is no further information to be disclosed pursuant to Rule 17 Schedule Two paragraph (g) of the AIM Rules for Companies in respect of the appointment of Cynthia Collins.

    About MaxCyte

    At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X and LinkedIn.

    MaxCyte Contacts:

    US IR Adviser

    Gilmartin Group

    David Deuchler, CFA

    +1 415-937-5400

    [email protected]

    US Media Relations

    Spectrum Science

    Jordan Vines

    [email protected]

    +1 540-629-3137

    Nominated Adviser and Joint Corporate Broker

    Panmure Liberum

    Emma Earl / Freddy Crossley

    Corporate Broking

    Rupert Dearden

    +44 (0)20 7886 2500

    UK IR Adviser

    ICR Consilium

    Mary-Jane Elliott

    Chris Welsh

    +44 (0)203 709 5700

    [email protected]



    Primary Logo

    Get the next $CERT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERT
    $MXCT
    $PSTX

    CompanyDatePrice TargetRatingAnalyst
    Certara Inc.
    $CERT
    5/8/2025$14.00Equal Weight → Overweight
    Barclays
    Certara Inc.
    $CERT
    2/27/2025$16.00Buy
    TD Cowen
    Poseida Therapeutics Inc.
    $PSTX
    12/2/2024$10.00Overweight → Neutral
    Piper Sandler
    Certara Inc.
    $CERT
    9/27/2024$16.00Neutral → Buy
    UBS
    Certara Inc.
    $CERT
    4/10/2024$23.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Certara Inc.
    $CERT
    4/4/2024Mkt Perform
    JMP Securities
    Certara Inc.
    $CERT
    2/26/2024$19.00Market Perform
    Leerink Partners
    Certara Inc.
    $CERT
    12/7/2023$17.00Neutral
    UBS
    More analyst ratings

    $CERT
    $MXCT
    $PSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Certara upgraded by Barclays with a new price target

      Barclays upgraded Certara from Equal Weight to Overweight and set a new price target of $14.00

      5/8/25 8:23:49 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • TD Cowen initiated coverage on Certara with a new price target

      TD Cowen initiated coverage of Certara with a rating of Buy and set a new price target of $16.00

      2/27/25 6:17:48 AM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Poseida Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Poseida Therapeutics from Overweight to Neutral and set a new price target of $10.00

      12/2/24 10:07:39 AM ET
      $PSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CERT
    $MXCT
    $PSTX
    SEC Filings

    See more
    • MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - MAXCYTE, INC. (0001287098) (Filer)

      6/18/25 4:58:53 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form DEFA14A filed by MaxCyte Inc.

      DEFA14A - MAXCYTE, INC. (0001287098) (Filer)

      5/29/25 4:30:10 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Certara Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Certara, Inc. (0001827090) (Filer)

      5/22/25 4:51:14 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology

    $CERT
    $MXCT
    $PSTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Masoud Maher bought $489,066 worth of shares (100,000 units at $4.89) (SEC Form 4)

      4 - MAXCYTE, INC. (0001287098) (Issuer)

      6/10/24 5:55:54 PM ET
      $MXCT
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $CERT
    $MXCT
    $PSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Human Resources Officer Anhalt Rona converted options into 7,146 shares and covered exercise/tax liability with 1,965 shares (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      6/2/25 4:58:36 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • SVP and General Counsel Corcoran Daniel converted options into 7,940 shares, covered exercise/tax liability with 6,607 shares and converted options into 14,888 units of Comon Stock (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      6/2/25 4:57:11 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology
    • Director Walsh Matthew M converted options into 11,928 shares, increasing direct ownership by 6% to 197,559 units (SEC Form 4)

      4 - Certara, Inc. (0001827090) (Issuer)

      5/22/25 5:07:31 PM ET
      $CERT
      Computer Software: Prepackaged Software
      Technology